Srs Capital Advisors, Inc. Akero Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $1.5 Billion
- Q4 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 22 shares of AKRO stock, worth $1,232. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22Holding current value
$1,232% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
193Shares Held
74.6MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$442 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$397 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$332 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$313 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$293 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.6B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...